ASO Author Reflections: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma
Recent clinical trials have reported superior outcomes using neoadjuvant immunotherapy compared with surgery followed by adjuvant immunotherapy alone for resectable patients with clinical stage III/IV melanoma, with practicechanging clinical implications. 1,2However, investigation into the optimal agent and dosing schedule is ongoing.
Authors
- Mohammad Saad Farooq (ORCID: https://orcid.org/0009-0009-8493-6976)
- Neha Shafique (ORCID: https://orcid.org/0000-0001-7219-2839)
- Giorgos C. Karakousis
Institutions
- Hospital of the University of Pennsylvania (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1245/s10434-025-18456-6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00